Back to search results

Targeted Radiation for Metastatic Sarcoma in Children and Young Adults

This study is for children, adolescents, and young adults (up to 39 years old) with metastatic sarcoma, including Ewing sarcoma and rhabdomyosarcoma. It's looking at whether giving consolidative radiation therapy (cRT) — treatment to kill any remaining cancer cells after initial therapy — to metastatic sites can improve how long patients live without their cancer returning. The study aims to enroll 70 participants. Success for this study would mean that patients receiving this targeted radiation have a better chance of staying cancer-free compared to historical data. The current recruitment status is unclear.

Study design
This is a single-arm study, meaning all participants will receive the consolidative radiation therapy. It plans to enroll 70 participants.
What's involved
Not specified in the trial record.
Compensation
Not stated in the trial record.
Follow-up
The primary goal is to measure how long patients live without their cancer returning, which will be assessed at 2 years.

AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.

NCT06796543

Targeted Oligometastatic Radiation in Pediatric and Young Adult Patients With Soft Tissue and Bone Sarcoma

Recruiting
NAUp to 39InterventionalSupportive care
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
~70 participants
Updated 2026-07-13 on ClinicalTrials.gov
What's tested:Consolidative radiation therapy (cRT)

At a glance

Recruiting sites
3 of 3 listed sites are recruiting right now
RecruitingSuspended, closed, or not yet open
What they're measuring
Event free survival
Measured over 2 years

Conditions

Metastatic Sarcoma
Radiation Therapy Patient
Ewing Sarcoma
Rhabdomyosarcoma

Explore related trials

Ewing SarcomaRhabdomyosarcomaSarcoma

Where it's being run

3 sites across 3 states
District of Columbia1
Maryland1
Minnesota1

Study leadership

  • Sahaja Acharya, MD · PRINCIPAL_INVESTIGATOR · SKCCC Johns Hopkins Medical Institution

Who to contact

Sahaja Acharya, MD
[email protected]
4432877889
Email the study team

Opens a ready-to-send draft in your own email app — review before sending.

Do you actually qualify for this trial?

Add a private profile and we'll compare every criterion below against your situation — and tell you which ones are met, uncertain, or excluding.

Check eligibility for this trial ~2 min · HIPAA-protected · delete anytime
Eligibility criteria

Inclusion

Patients must be aged \< 39 years at time of enrollment.
Patients must have a Karnofsky or Lansky performance score of 70 or greater or Eastern Cooperative Oncology Group (ECOG) performance status of 0-1.
Patients must have newly diagnosed histologically or molecularly confirmed soft tissue or bone sarcoma at any site.
Patients must have metastatic disease that is measurable and this is defined as at least one lesion discontinuous from the primary that can be accurately measured in at least one dimension (longest diameter to be recorded) as \> 3mm with CT scan within 3 weeks from treatment start.
Patients must have a Karnofsky or Lansky performance score of 70 or greater or ECOG performance status of 0-1.
Patients must have radiographic, histologic or molecular confirmation of progressive soft tissue or bone sarcoma at any site that was initially diagnosed at age \< 39 years. Progression includes progression at a new site or known sites of prior disease (e.g. recurrent).
Patients must have metastatic disease that is measurable and this is defined as at least one lesion discontinuous from the primary that can be accurately measured in at least one dimension (longest diameter to be recorded) as \> 3mm with CT scan
Radiation to at least one site is being recommended as part of second line therapy.

Exclusion

Brain or intracranial metastases, including leptomeningeal disease
Clinical or radiologic evidence of spinal cord compression requiring emergent radiation treatment
Positive bone marrow biopsy for non-pelvic primary and greater than eight bone metastases. Presence of parenchymal lung metastases is considered as one metastasis, irrespective of how many lung nodules are present.
Evidence of any non-measurable metastatic disease including but not limited to leptomeningeal disease, malignant ascites and malignant pleural or pericardial effusions.
Pregnancy
Brain or intracranial metastases, including leptomeningeal disease
Clinical or radiologic evidence of spinal cord compression requiring emergent radiation treatment
Evidence of any non-measurable metastatic disease including but not limited to leptomeningeal disease, malignant ascites and malignant pleural or pericardial effusions.
Pregnancy

What this trial measures

  • Event free survival2 years

    2-year event free survival (EFS1) after cRT in patients with oligometastatic sarcoma as compared to historical control (applies to newly diagnosed (Stratum A) patients.